WilmerHale client AVEO Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its option to purchase 4,500,000 shares at the public offering price of $0.50 per share. The exercise of the option increased the amount of net proceeds raised in the offering, after underwriting discounts and estimated offering expenses, to approximately $15.5 million.

Cynthia Mazareas led the WilmerHale team on the transaction, which included Avery Reaves and Jared Iverson.

The press release can be found on aveooncology.com.